Division of Hematology and Oncology Archive — Page 9 of 15
-
April 30, 2020
Initiative to explore COVID-19 outcomes in cancer patients
A multi-institutional consortium led by Vanderbilt-Ingram Cancer Center (VICC) is collecting data on cancer patients with COVID-19 as part of a rapid effort to understand the unique effects the coronavirus has on this vulnerable population. -
April 23, 2020
Health workers sought for hydroxychloroquine study
Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection. -
March 5, 2020
One-two punch for cancer
A drug combination effectively killed aggressive blood cancers in cell and animal models; now it’s being tested in patients. -
February 20, 2020
Post-transplant diabetes may be reversible: study
Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report. -
February 13, 2020
Advocacy group’s gift boosts lung cancer research efforts
An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer. -
February 5, 2020
Vanderbilt-Ingram Cancer Center researchers included in ASCO annual report
Two researchers from Vanderbilt-Ingram Cancer Center (VICC) are featured in Clinical Cancer Advances 2020: ASCO’s Annual Report on Progress Against Cancer. -
February 5, 2020
Vanderbilt-Ingram Cancer Center patient first for new cell engineering platform
Rhea Dodd is the first patient treated with an experimental cancer vaccine derived from a completely new cell engineering platform.